BioNotebook: Halozyme falters; Baxter acquires Chatham; Celgene buys Acceleron shares; and IPOs lose momentum
This article was originally published in Scrip
Executive Summary
Halozyme Therapeutics closed down 27.3% at $8.43 per share on 4 April after it revealed a temporary halt for an ongoing Phase II clinical trial testing the San Diego-based company's PEGPH20 in pancreatic cancer patients treated with nab-paclitaxel and gemcitabine.
You may also be interested in...
AskBio Knocks Down Enough Hurdles To Raise $235m For Its Gene Therapy Platform
While some companies rushed into gene therapy and exited after a single setback, Asklepios BioPharmaceutical quietly advanced its programs, identifying challenges and overcoming them one at a time. Now, it's ready to advance multiple programs into the clinic.
Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?
Roche's emicizumab, Alnylam's fitusiran and multiple gene therapies may soon steal market share from established clotting factors sold by Shire, Novo Nordisk and others, but safety is a key consideration for physicians and patients.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.